Volpicelli J R, Clay K L, Watson N T, O'Brien C P
Department of Psychiatry and Psychology, University of Pennsylvania, Philadelphia, USA.
J Clin Psychiatry. 1995;56 Suppl 7:39-44.
The pooled results of 99 subjects from our Veterans Affairs population show that naltrexone-treated subjects had a greater reduction in alcohol craving, number of drinking days, and alcoholic relapse rates when compared with placebo-treated subjects. Based on our findings and results from other double-blind trials of naltrexone, we conclude that naltrexone is a safe and useful adjunct in the rehabilitation of alcohol-dependent patients. Increased baseline levels of psychological distress and craving as well as higher levels of somatic distress, anxiety, phobic anxiety, and obsessive-compulsive symptoms predicted an increased number of drinking days during the study. Significant interactions between naltrexone treatment, initial craving, and somatic distress suggest that naltrexone may be useful for subjects who present with high levels of craving and somatic symptoms.
我们对退伍军人事务部人群中99名受试者的汇总结果显示，与接受安慰剂治疗的受试者相比，接受纳曲酮治疗的受试者在酒精渴望、饮酒天数和酒精复发率方面有更大程度的降低。基于我们的研究结果以及纳曲酮其他双盲试验的结果，我们得出结论，纳曲酮是酒精依赖患者康复过程中一种安全且有用的辅助药物。心理困扰和渴望的基线水平升高，以及更高水平的躯体困扰、焦虑、恐惧焦虑和强迫症状预示着研究期间饮酒天数增加。纳曲酮治疗、初始渴望和躯体困扰之间的显著相互作用表明，纳曲酮可能对有高度渴望和躯体症状的受试者有用。
